Targeting the HGF/Met signaling pathway in cancer therapy

Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197

(2011) Sudharshan Eathiraj et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hepatocyte growth factor twenty years on: Much more than a growth factor

(2011) Takahiro Nakamura et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

(2011) L. Liu et al.   MOLECULAR CANCER THERAPEUTICS

A direct role for Met endocytosis in tumorigenesis

(2011) Carine Joffre et al.   NATURE CELL BIOLOGY

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

(2010) B.-S. Pan et al.   CANCER RESEARCH

MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity

(2010) J. W. Tyner et al.   CANCER RESEARCH

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

(2010) P. J. Rosen et al.   CLINICAL CANCER RESEARCH

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma

(2010) Yoshinori Suzuki et al.   INTERNATIONAL JOURNAL OF CANCER

MET Pathway as a Therapeutic Target

(2010) Eric S. Kim et al.   Journal of Thoracic Oncology

BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro

(2010) Y. Dai et al.   MOLECULAR CANCER THERAPEUTICS

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation

(2010) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

(2009) Wenqing Qi et al.   BMC CANCER

Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models

(2009) Yuko Kishi et al.   CANCER SCIENCE

E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

(2009) Takayuki Nakagawa et al.   CANCER SCIENCE

Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells

(2009) E. Matteucci et al.   CARCINOGENESIS

Directed Discovery of Agents Targeting the Met Tyrosine Kinase Domain by Virtual Screening

(2009) Megan L. Peach et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

(2009) Gretchen M. Schroeder et al.   JOURNAL OF MEDICINAL CHEMISTRY

In Vivo Positron Emission Tomography (PET) Imaging of Mesenchymal−Epithelial Transition (MET) Receptor

(2009) Chunying Wu et al.   JOURNAL OF MEDICINAL CHEMISTRY

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

(2009) James W Welsh et al.   Radiation Oncology

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30

(2008) Lars R. Perk et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met

(2008) Cristina Basilico et al.   JOURNAL OF BIOLOGICAL CHEMISTRY